MedTrace Logo

Exploring the Anti-ageing Effects of Metformin in COPD

NCT06999343 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 212

Last updated 2025-05-31

No results posted yet for this study

Summary

Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1.

Main objective:

To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo.

Participants will take metformin (850mg) or placebo twice daily for 3 years.

Conditions

Interventions

DRUG

Metformin 850Mg Tab

Tolerance phase dose: 850mg/24h for 2 weeks. Treatment dose: 1700 mg twice daily.

OTHER

Placebo

Tolerance phase dose: One tablet/24h for 2 weeks. Treatment dose: Two tablets twice daily.

Sponsors & Collaborators

  • Fundación Instituto de Investigación Sanitaria de Navarra

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2029-05-01
Completion
2029-09-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06999343 on ClinicalTrials.gov